Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | STAT1 | P42224 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805077 | 0.85 | NPC1 (0.65) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7122333 | 0.85 | NPC1 (0.68) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7123957 | 0.82 | NPC1 (0.80) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4805043 | 0.81 | NPC1 (0.60) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4805607 | 0.80 | NPC1 (0.65) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL22733326 | 0.79 | KDM4E (0.77) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL27076573 | 0.78 | NPC1 (0.69) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7157591 | 0.78 | NPC1 (0.69) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7115028 | 0.78 | NPC1 (0.69) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4802927 | 0.76 | NPC1 (0.62) | NPC1ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | ZHANG XUQING | 2008-09-11 | — | — | US | disclosed |
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | ZHANG XUQING | 2008-09-11 | — | — | US | disclosed |
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | ZHANG XUQING | 2008-09-11 | — | — | US | disclosed |
| US-7399767-B2 | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399767-B2 | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399767-B2 | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1846397-A1 | NOVEL HETEROCYCLIC BENZOY[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| US-20060205741-A1 | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006078834-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205741-A1 | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | GPER1, ESR1, ESR2 | NPC1 4199/4885ALDH1A1 2052/4885KDM4E 1738/4885 |
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | GPER1, ESR1, ESR2 | NPC1 4199/4885ALDH1A1 2052/4885KDM4E 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.